Maria Jimenez-Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Jimenez-Sanchez has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- David C. Rubinsztein
Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK
7 shared publications - David C. Rubinsztein
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
7 shared publications Fiona M. Menzies
Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, UK
7 shared publications- Wendy Noble
University of Exeter, UK
7 shared publications - Angeleen Fleming
Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
4 shared publications - Cara Louise Croft
Centre For Neuroscience, Surgery and Trauma, The Blizard Institute Queen Mary University of London London UK
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by MDPI AG in Preprints.org
P2X7 Receptor Signalling as a Danger-Amplifying Hub in Lewy Body Diseases
Background: Lewy body diseases (LBD), encompassing Parkinson’s disease (PD), Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), are characterised by pathological α-synuclein (αSyn) aggregation, glial dysfunction and a lack of disease-modifying therapies. Converging evidence from α-synucleinopathy models, human neurodegenerative tissue and purinergic target-engagement studies implicates the glial ATP-gated P2X7 receptor (P2X7R) as a potential regulator of inflammatory and proteostatic stress.Main body: This review evaluates P2X7R as a candidate danger-amplifying hub in LBD. We propose that αSyn-rich, ATP-enriched microenvironments may shift glial P2X7R signalling from surveillance and clearance towards maladaptive effector programmes involving excitotoxic vulnerability, NF-κB/MAPK activation, inflammasome engagement, autophagic-lysosomal dysfunction and altered extracellular vesicle biology. We further consider human post-mortem, positron emission tomography (PET) imaging and preclinical evidence, highlighting that direct LBD-specific evidence remains limited and that P2X7R should be interpreted as a context-dependent glial effector receptor rather than a generic marker of inflammation. Conclusions: This framework provides a testable model in which chronic P2X7R activation may contribute to non-cell-autonomous neuronal injury and impaired αSyn handling. P2X7R therefore represents a promising but incompletely validated therapeutic target in LBD. Future studies should prioritise human validation, PET-based disease staging, multicellular αSyn models with cell-type-specific P2RX7 manipulation, and biomarker strategies that distinguish receptor availability from functional target engagement.
- 2 November 2026
- Published by MDPI AG in Preprints.org
Open AccessP2X7 Receptor Signalling as a Danger-Amplifying Hub in Lewy Body Diseases
Background: Lewy body diseases (LBD), encompassing Parkinson’s disease (PD), Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), are characterised by pathological α-synuclein (αSyn) aggregation, glial dysfunction and a lack of disease-modifying therapies. Converging evidence from α-synucleinopathy models, human neurodegenerative tissue and purinergic target-engagement studies implicates the glial ATP-gated P2X7 receptor (P2X7R) as a potential regulator of inflammatory and proteostatic stress.Main body: This review evaluates P2X7R as a candidate danger-amplifying hub in LBD. We propose that αSyn-rich, ATP-enriched microenvironments may shift glial P2X7R signalling from surveillance and clearance towards maladaptive effector programmes involving excitotoxic vulnerability, NF-κB/MAPK activation, inflammasome engagement, autophagic-lysosomal dysfunction and altered extracellular vesicle biology. We further consider human post-mortem, positron emission tomography (PET) imaging and preclinical evidence, highlighting that direct LBD-specific evidence remains limited and that P2X7R should be interpreted as a context-dependent glial effector receptor rather than a generic marker of inflammation. Conclusions: This framework provides a testable model in which chronic P2X7R activation may contribute to non-cell-autonomous neuronal injury and impaired αSyn handling. P2X7R therefore represents a promising but incompletely validated therapeutic target in LBD. Future studies should prioritise human validation, PET-based disease staging, multicellular αSyn models with cell-type-specific P2RX7 manipulation, and biomarker strategies that distinguish receptor availability from functional target engagement.
- Open Access
- 12 October 2026
- Published by Springer Nature in Research Square
An astrocyte-neuron HSPB1 axis preserves lysosomal integrity and protects from tau pathology
Alzheimer’s disease (AD) is characterized by a decline in neuronal proteostasis that favours the accumulation of misfolded proteins. Molecular chaperones are essential to prevent protein aggregation and, although typically studied as intracellular proteins, chaperones can also be secreted with functions that remain to be elucidated. Here, we identify a mechanism by which astrocyte-secreted HSPB1 is internalized by neurons to increase neuronal proteostasis and prevent the aggregation of pathological tau. We characterized HSPB1 as an astrocytic protein that can also be acquired post-transcriptionally by neurons in AD brain and in culture. Upon internalization into the endolysosomal system through macropinocytosis, HSPB1 prevents lysosomal damage and promotes tau clearance, thereby positioning HSPB1 as a key protein in maintaining organelle and protein homeostasis across astrocyte-neuronal networks. This work identifies a mechanism by which astrocytes boost neuronal capacity to protect from protein aggregation in neurodegeneration.
- 12 October 2026
- Published by Springer Nature in Research Square
Open AccessAn astrocyte-neuron HSPB1 axis preserves lysosomal integrity and protects from tau pathology
Alzheimer’s disease (AD) is characterized by a decline in neuronal proteostasis that favours the accumulation of misfolded proteins. Molecular chaperones are essential to prevent protein aggregation and, although typically studied as intracellular proteins, chaperones can also be secreted with functions that remain to be elucidated. Here, we identify a mechanism by which astrocyte-secreted HSPB1 is internalized by neurons to increase neuronal proteostasis and prevent the aggregation of pathological tau. We characterized HSPB1 as an astrocytic protein that can also be acquired post-transcriptionally by neurons in AD brain and in culture. Upon internalization into the endolysosomal system through macropinocytosis, HSPB1 prevents lysosomal damage and promotes tau clearance, thereby positioning HSPB1 as a key protein in maintaining organelle and protein homeostasis across astrocyte-neuronal networks. This work identifies a mechanism by which astrocytes boost neuronal capacity to protect from protein aggregation in neurodegeneration.
- Open Access
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77822
Temporal Trajectories of the Tau Aggregate Interactome Reveal Stage‐Specific Vulnerabilities in Alzheimer's Disease
Tau aggregation is a central pathological feature of Alzheimer's disease, yet how different forms of tau—ranging from monomers to small soluble aggregates and mature fibrils—interact with the cellular environment remains poorly understood. Here, we combine immunoaffinity proteomics with single‐molecule techniques and super‐resolution microscopy to systematically map the tau interactome across defined aggregation states, spanning monomeric tau, nanoscopic soluble aggregates, and fibrillar species. Using post‐mortem Alzheimer's disease brain tissue, we identify distinct functional modules associated with different aggregation states: while proteostasis factors and immune‐related proteins preferentially associate with nanoscopic aggregates (oligomers), cytoskeletal, metabolic, and RNA‐binding proteins are enriched for mature fibrillar tau. Single‐molecule microscopy directly confirms this conformation‐dependent recruitment for key interactors including Hsp70‐2, ENO1, hnRNPA1, APP, EAAT4, and ubiquitin. A primary‐neuron system with accelerated tau aggregation is used to model these findings in a controlled system, showing striking similarities to the brain samples. Finally, pseudotime analysis reconstructs a progressive remodelling of the tau interactome across disease progression, revealing stage‐specific pathway vulnerabilities. Together, these results establish a temporally resolved framework for tau pathology shaped by protein interactions and identify potential therapeutic intervention points for investigation across stages of disease.
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77822
Open AccessTemporal Trajectories of the Tau Aggregate Interactome Reveal Stage‐Specific Vulnerabilities in Alzheimer's Disease
Tau aggregation is a central pathological feature of Alzheimer's disease, yet how different forms of tau—ranging from monomers to small soluble aggregates and mature fibrils—interact with the cellular environment remains poorly understood. Here, we combine immunoaffinity proteomics with single‐molecule techniques and super‐resolution microscopy to systematically map the tau interactome across defined aggregation states, spanning monomeric tau, nanoscopic soluble aggregates, and fibrillar species. Using post‐mortem Alzheimer's disease brain tissue, we identify distinct functional modules associated with different aggregation states: while proteostasis factors and immune‐related proteins preferentially associate with nanoscopic aggregates (oligomers), cytoskeletal, metabolic, and RNA‐binding proteins are enriched for mature fibrillar tau. Single‐molecule microscopy directly confirms this conformation‐dependent recruitment for key interactors including Hsp70‐2, ENO1, hnRNPA1, APP, EAAT4, and ubiquitin. A primary‐neuron system with accelerated tau aggregation is used to model these findings in a controlled system, showing striking similarities to the brain samples. Finally, pseudotime analysis reconstructs a progressive remodelling of the tau interactome across disease progression, revealing stage‐specific pathway vulnerabilities. Together, these results establish a temporally resolved framework for tau pathology shaped by protein interactions and identify potential therapeutic intervention points for investigation across stages of disease.
- Open Access
- 8 October 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1) , 2409563
Truncated tau disrupts autophagy and endolysosomal systems
- 8 October 2024
- Published by Taylor & Francis in Autophagy Reports
- Vol. 3 (1) , 2409563
Open AccessTruncated tau disrupts autophagy and endolysosomal systems
- Open Access
- 15 July 2024
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 81 (1) , 1-16
Truncated tau interferes with the autophagy and endolysosomal pathway and results in lipid accumulation
The autophagy-lysosomal pathway plays a critical role in the clearance of tau protein aggregates that deposit in the brain in tauopathies, and defects in this system are associated with disease pathogenesis. Here, we report that expression of Tau35, a tauopathy-associated carboxy-terminal fragment of tau, leads to lipid accumulation in cell lines and primary cortical neurons. Our findings suggest that this is likely due to a deleterious block of autophagic clearance and lysosomal degradative capacity by Tau35. Notably, upon induction of autophagy by Torin 1, Tau35 inhibited nuclear translocation of transcription factor EB (TFEB), a key regulator of lysosomal biogenesis. Both cell lines and primary cortical neurons expressing Tau35 also exhibited changes in endosomal protein expression. These findings implicate autophagic and endolysosomal dysfunction as key pathological mechanisms through which disease-associated tau fragments could lead to the development and progression of tauopathy.
- 15 July 2024
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 81 (1) , 1-16
Open AccessTruncated tau interferes with the autophagy and endolysosomal pathway and results in lipid accumulation
The autophagy-lysosomal pathway plays a critical role in the clearance of tau protein aggregates that deposit in the brain in tauopathies, and defects in this system are associated with disease pathogenesis. Here, we report that expression of Tau35, a tauopathy-associated carboxy-terminal fragment of tau, leads to lipid accumulation in cell lines and primary cortical neurons. Our findings suggest that this is likely due to a deleterious block of autophagic clearance and lysosomal degradative capacity by Tau35. Notably, upon induction of autophagy by Torin 1, Tau35 inhibited nuclear translocation of transcription factor EB (TFEB), a key regulator of lysosomal biogenesis. Both cell lines and primary cortical neurons expressing Tau35 also exhibited changes in endosomal protein expression. These findings implicate autophagic and endolysosomal dysfunction as key pathological mechanisms through which disease-associated tau fragments could lead to the development and progression of tauopathy.
- Open Access
- 28 June 2024
- Published by Springer Nature in Research Square
Truncated tau interferes with the autophagy and endolysosomal pathway and results in lipid accumulation.
The autophagy-lysosomal pathway plays a critical role in the clearance of tau protein aggregates that deposit in the brain in tauopathies, and defects in this system are associated with disease pathogenesis. Here, we report that expression of Tau35, a tauopathy-associated carboxy-terminal fragment of tau, leads to lipid accumulation in cell lines and primary cortical neurons. Our findings suggest that this is likely due to a deleterious block of autophagic clearance and lysosomal degradative capacity by Tau35. Notably, upon induction of autophagy by Torin 1, Tau35 inhibited nuclear translocation of transcription factor EB (TFEB), a key regulator of lysosomal biogenesis. Both cell lines and primary cortical neurons expressing Tau35 also exhibited deficits in endosomal protein expression. These findings implicate autophagic and endolysosomal dysfunction as key pathological mechanisms through which disease-associated tau fragments could lead to the development and progression of tauopathy.
- 28 June 2024
- Published by Springer Nature in Research Square
Open AccessTruncated tau interferes with the autophagy and endolysosomal pathway and results in lipid accumulation.
The autophagy-lysosomal pathway plays a critical role in the clearance of tau protein aggregates that deposit in the brain in tauopathies, and defects in this system are associated with disease pathogenesis. Here, we report that expression of Tau35, a tauopathy-associated carboxy-terminal fragment of tau, leads to lipid accumulation in cell lines and primary cortical neurons. Our findings suggest that this is likely due to a deleterious block of autophagic clearance and lysosomal degradative capacity by Tau35. Notably, upon induction of autophagy by Torin 1, Tau35 inhibited nuclear translocation of transcription factor EB (TFEB), a key regulator of lysosomal biogenesis. Both cell lines and primary cortical neurons expressing Tau35 also exhibited deficits in endosomal protein expression. These findings implicate autophagic and endolysosomal dysfunction as key pathological mechanisms through which disease-associated tau fragments could lead to the development and progression of tauopathy.
- Open Access
- 22 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (12) , eadk9884
Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
Molecular chaperones are protective in neurodegenerative diseases by preventing protein misfolding and aggregation, such as extracellular amyloid plaques and intracellular tau neurofibrillary tangles in Alzheimer’s disease (AD). In addition, AD is characterized by an increase in astrocyte reactivity. The chaperone HSPB1 has been proposed as a marker for reactive astrocytes; however, its astrocytic functions in neurodegeneration remain to be elucidated. Here, we identify that HSPB1 is secreted from astrocytes to exert non–cell-autonomous protective functions. We show that in human AD brain, HSPB1 levels increase in astrocytes that cluster around amyloid plaques, as well as in the adjacent extracellular space. Moreover, in conditions that mimic an inflammatory reactive response, astrocytes increase HSPB1 secretion. Concomitantly, astrocytes and neurons can uptake astrocyte-secreted HSPB1, which is accompanied by an attenuation of the inflammatory response in reactive astrocytes and reduced pathological tau inclusions. Our findings highlight a protective mechanism in disease conditions that encompasses the secretion of a chaperone typically regarded as intracellular.
- 22 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (12) , eadk9884
Open AccessReactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
Molecular chaperones are protective in neurodegenerative diseases by preventing protein misfolding and aggregation, such as extracellular amyloid plaques and intracellular tau neurofibrillary tangles in Alzheimer’s disease (AD). In addition, AD is characterized by an increase in astrocyte reactivity. The chaperone HSPB1 has been proposed as a marker for reactive astrocytes; however, its astrocytic functions in neurodegeneration remain to be elucidated. Here, we identify that HSPB1 is secreted from astrocytes to exert non–cell-autonomous protective functions. We show that in human AD brain, HSPB1 levels increase in astrocytes that cluster around amyloid plaques, as well as in the adjacent extracellular space. Moreover, in conditions that mimic an inflammatory reactive response, astrocytes increase HSPB1 secretion. Concomitantly, astrocytes and neurons can uptake astrocyte-secreted HSPB1, which is accompanied by an attenuation of the inflammatory response in reactive astrocytes and reduced pathological tau inclusions. Our findings highlight a protective mechanism in disease conditions that encompasses the secretion of a chaperone typically regarded as intracellular.
- Open Access
- 11 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (2) , 346-366
Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
Astrocytes associate with amyloid plaques in Alzheimer's disease (AD). Astrocytes react to changes in the brain environment, including increasing concentrations of amyloid‐β (Aβ). However, the precise response of astrocytes to soluble small Aβ oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to media from neurons that express the human amyloid precursor protein (APP) transgene with the double Swedish mutation (APPSwe), and which contains APP‐derived fragments, including soluble human Aβ oligomers. We then used proteomics to investigate changes in the astrocyte secretome. Our data show dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease. image
- 11 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (2) , 346-366
Open AccessProteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
Astrocytes associate with amyloid plaques in Alzheimer's disease (AD). Astrocytes react to changes in the brain environment, including increasing concentrations of amyloid‐β (Aβ). However, the precise response of astrocytes to soluble small Aβ oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to media from neurons that express the human amyloid precursor protein (APP) transgene with the double Swedish mutation (APPSwe), and which contains APP‐derived fragments, including soluble human Aβ oligomers. We then used proteomics to investigate changes in the astrocyte secretome. Our data show dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease. image
- Open Access
Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aß
Astrocytes associate with amyloid plaques in Alzheimer’s disease (AD). Astrocytes react to changes in the brain environment, including to increasing concentrations of amyloid-ß (Aß). However, the precise response of astrocytes to soluble small Aß oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to neuronal media containing soluble human Aß oligomers and used proteomics to investigate changes in the astrocyte secretome. Our data shows dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease.
Open AccessProteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aß
Astrocytes associate with amyloid plaques in Alzheimer’s disease (AD). Astrocytes react to changes in the brain environment, including to increasing concentrations of amyloid-ß (Aß). However, the precise response of astrocytes to soluble small Aß oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to neuronal media containing soluble human Aß oligomers and used proteomics to investigate changes in the astrocyte secretome. Our data shows dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease.
- Open Access
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 1036587
Editorial: Autophagy in the central nervous system: Focus on neurons, glia and neuron-glia interactions
Editorial: Autophagy in the central nervous system: Focus on neurons, glia and neuron-glia interactions
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 1036587
Open AccessEditorial: Autophagy in the central nervous system: Focus on neurons, glia and neuron-glia interactions
Editorial: Autophagy in the central nervous system: Focus on neurons, glia and neuron-glia interactions